Cannabis Market in Switzerland

Switzerland has carved out a distinctive position in the European cannabis landscape through its progressive approach to CBD products, medical cannabis pilot programs, and a pragmatic regulatory philosophy. The Swiss market is most notable for its thriving legal CBD industry, which exploded after authorities confirmed in 2016 that cannabis products containing less than 1% THC (higher than the EU's 0.2-0.3% threshold) are legal for sale. This higher THC threshold created a commercially viable CBD flower market that closely resembles traditional cannabis in appearance, aroma, and taste — making Switzerland a unique case study in low-THC cannabis commercialization.

The Swiss CBD market grew rapidly, with products sold in tobacco shops, specialty stores, and online retailers. At its peak, the market included hundreds of producers and retailers, with annual revenues estimated at CHF 100 million or more. Products include CBD flower, oils, cosmetics, and edibles. However, the market has matured significantly, with consolidation reducing the number of active companies and price competition compressing margins. Companies like Cannabis Suisse Corp (CSUI) have been among the publicly traded entities operating in this space, though most Swiss CBD companies remain private.

In 2022, Switzerland took a significant step by authorizing pilot programs for recreational cannabis in several cities, including Basel, Zurich, Bern, and Lausanne. These scientifically monitored studies allow selected participants to purchase cannabis from pharmacies and observe the effects of regulated access on consumption patterns, health outcomes, and public safety. The pilot approach reflects Switzerland's tradition of evidence-based drug policy, which also produced the country's pioneering harm reduction programs for harder drugs. The results of these pilots, expected to inform policy over the next several years, could lead to broader recreational legalization.

Medical cannabis in Switzerland operates under a framework that has gradually expanded access. Until 2022, patients needed exceptional authorization from the Federal Office of Public Health for each cannabis prescription. Regulatory changes effective August 2022 simplified this process, allowing physicians to prescribe cannabis-based medicines directly for qualifying conditions without individual authorization. This change is expected to significantly increase the number of medical cannabis patients and create growth opportunities for pharmaceutical cannabis producers.